In breast cancer, MYC amplification is observed in approximately 15%–30% of cases, particularly in triple-negative breast cancer (TNBC) and HER2-positive subtypes, where it drives aggressive tumor behavior and resistance to standard therapies (Gao et al., 2023). This evidence concerns the gene MYC and neoplasm.